Clinicopathological significance of histological diversity in gastric adenocarcinoma with primitive enterocyte phenotype: A methylation-driven aggressive entity

Table 1 The comparison of clinicopathologic features and stratification in gastric adenocarcinoma with primitive enterocyte phenotype

Parament	GAPEP (n = 134)	CGC-P (n = 92)	CGC (n = 274)	HAC (n = 49)	GAED (n = 63)	P value
						GAPEP vs CGC	GAPEP vs CGC-P	CGC-P vs CGC	HAC vs GAED
Age (years)						< 0.01	< 0.05	0.4103	< 0.05
> 65	74	38	100	21	39
≤ 65	60	54	174	28	24
Gender						0.407	0.4426	0.1206	0.568
Male	102	74	198	35	48
Female	32	18	76	14	15
Location						0.749	0.6455	0.4288	0.4778
Fundus-body and cardia	84	60	166	32	37
Antrum	51	32	108	17	26
Size (cm)						< 0.0001	< 0.0001	0.5841	0.2630
> 5	65	21	219	27	28
≤ 5	69	71	55	22	35
Histological grade						< 0.0001	< 0.01	0.4677	< 0.001
G1-2	92	47	128	25	53
G3	41	45	146	24	10
JGCA type						0.0001	0.0822	0.1309	< 0.001
Differentiated	99	58	148	26	54
Undifferentiated	35	34	126	23	9
Vascular invasion						0.846	0.6119	0.6883	0.1278
Positive	105	70	214	41	45
Negative	28	22	60	8	18
Perineural invasion						< 0.0001	< 0.05	0.1168	0.7850
Positive	98	58	158	37	46
Negative	31	34	136	12	17
T-staging						< 0.001	0.4323	< 0.0001	0.8249
T2-3	9	20	53	11	16
T4	124	72	221	38	47
AJCC-staging						0.6875	0.0967	0.127	0.5434
I-II	42	39	92	14	22
III-IV	91	53	182	35	41
Tumor budding						0.0656	0.6422	0.2247	NA
Bd1	16	16	47	NA	NA
Bd 2-3	43	52	227	NA	NA
MMR
pMMR	86	209	71	30	40	< 0.05	0.9554	0.0571	0.7564
dMMR	13	63	11	6	6
p53						0.001	0.5465	< 0.05	0.7880
Mutant type	81	59	128	28	42
Wild type	21	19	83	6	11
HER2						< 0.01	0.3301	0.1179	0.6284
Amplification	29	16	30	8	14
Not amplification	93	72	228	36	45

GAPEP: Gastric adenocarcinoma with primitive enterocyte phenotype; CGC: Conventional gastric cancer; CGC-P: Conventional gastric cancer expressing primitive phenotypic markers; HAC: Hepatoid adenocarcinoma; GAED: Gastric adenocarcinoma with enteroblastic differentiation; NA: Not available; JGCA: Japanese Gastric Cancer Association; AJCC: American Joint Committee on Cancer; MMR: Mismatched repair; pMMR: Proficient mismatched repair; dMMR: Defective mismatched repair; NA: Not available.